53 related articles for article (PubMed ID: 30591425)
41. Chemotherapy for mycosis fungoides and the Sézary syndrome.
Rosen ST; Foss FM
Hematol Oncol Clin North Am; 1995 Oct; 9(5):1109-16. PubMed ID: 8522487
[TBL] [Abstract][Full Text] [Related]
42. Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force.
Scarisbrick JJ; Hodak E; Bagot M; Stranzenbach R; Stadler R; Ortiz-Romero PL; Papadavid E; Evison F; Knobler R; Quaglino P; Vermeer MH
Eur J Cancer; 2018 Apr; 93():47-56. PubMed ID: 29477101
[TBL] [Abstract][Full Text] [Related]
43. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.
Trautinger F; Eder J; Assaf C; Bagot M; Cozzio A; Dummer R; Gniadecki R; Klemke CD; Ortiz-Romero PL; Papadavid E; Pimpinelli N; Quaglino P; Ranki A; Scarisbrick J; Stadler R; Väkevä L; Vermeer MH; Whittaker S; Willemze R; Knobler R
Eur J Cancer; 2017 May; 77():57-74. PubMed ID: 28365528
[TBL] [Abstract][Full Text] [Related]
44. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome.
Trautinger F; Knobler R; Willemze R; Peris K; Stadler R; Laroche L; D'Incan M; Ranki A; Pimpinelli N; Ortiz-Romero P; Dummer R; Estrach T; Whittaker S
Eur J Cancer; 2006 May; 42(8):1014-30. PubMed ID: 16574401
[TBL] [Abstract][Full Text] [Related]
45. New and established treatment options for mycosis fungoides and Sézary syndrome - an update.
Dugas-Breit S; Schulze HJ; Hallermann C
J Dtsch Dermatol Ges; 2014 Jul; 12(7):561-9. PubMed ID: 24889480
[TBL] [Abstract][Full Text] [Related]
46. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
47. Pralatrexate, a new hope for aggressive T-cell lymphomas?
Rueda A; Casanova M; Quero C; Medina-Pérez A
Clin Transl Oncol; 2009 Apr; 11(4):215-20. PubMed ID: 19380298
[TBL] [Abstract][Full Text] [Related]
48. Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review.
Stewart JR; Desai N; Rizvi S; Zhu H; Goff HW
Eur J Dermatol; 2018 Dec; 28(6):764-774. PubMed ID: 30591425
[TBL] [Abstract][Full Text] [Related]
49. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
50. Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy.
Kamijo H; Miyagaki T
Curr Treat Options Oncol; 2021 Jan; 22(2):10. PubMed ID: 33415447
[TBL] [Abstract][Full Text] [Related]
51. Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome.
Janiga J; Kentley J; Nabhan C; Abdulla F
Leuk Lymphoma; 2018 Mar; 59(3):562-577. PubMed ID: 29308723
[TBL] [Abstract][Full Text] [Related]
52. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome.
Lenihan DJ; Alencar AJ; Yang D; Kurzrock R; Keating MJ; Duvic M
Blood; 2004 Aug; 104(3):655-8. PubMed ID: 15073032
[TBL] [Abstract][Full Text] [Related]
53. Methotrexate and Pralatrexate.
Wood GS; Wu J
Dermatol Clin; 2015 Oct; 33(4):747-55. PubMed ID: 26433846
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]